

Yu Shen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4262865/publications.pdf>

Version: 2024-02-01

147
papers

10,309
citations

38742

50
h-index

33894

99
g-index

148
all docs

148
docs citations

148
times ranked

10709
citing authors

#	ARTICLE	IF	CITATIONS
1	Semiparametric copula-based regression modeling of semi-competing risks data. <i>Communications in Statistics - Theory and Methods</i> , 2022, 51, 7830-7845.	1.0	2
2	Combining primary cohort data with external aggregate information without assuming comparability. <i>Biometrics</i> , 2021, 77, 1024-1036.	1.4	12
3	A Bayesian semiparametric method for analyzing length-biased data. <i>Journal of Applied Statistics</i> , 2021, 48, 977-992.	1.3	0
4	Analyzing left-truncated and right-censored infectious disease cohort data with interval-censored infection onset. <i>Statistics in Medicine</i> , 2021, 40, 287-298.	1.6	2
5	Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer. <i>British Journal of Cancer</i> , 2021, 124, 1970-1977.	6.4	26
6	Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer. <i>Cancers</i> , 2021, 13, 2650.	3.7	11
7	Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer. <i>Annals of Internal Medicine</i> , 2021, 174, 602-612.	3.9	6
8	Design of phase III trials with long-term survival outcomes based on short-term binary results. <i>Statistics in Medicine</i> , 2021, 40, 4122-4135.	1.6	0
9	Inflammatory breast cancer appearance at presentation is associated with overall survival. <i>Cancer Medicine</i> , 2021, 10, 6261-6272.	2.8	10
10	Evaluation of overall survival and barriers to surgery for patients with breast cancer treated without surgery: a National Cancer Database analysis. <i>Npj Breast Cancer</i> , 2021, 7, 87.	5.2	7
11	Time to Consider a Personalized Approach to Incorporate Tomosynthesis Into Routine Breast Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2020, 112, 553-554.	6.3	1
12	Modeling the Coronavirus Disease 2019 Incubation Period: Impact on Quarantine Policy. <i>Mathematics</i> , 2020, 8, 1631.	2.2	10
13	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , 2020, 26, 1845-1851.	30.7	193
14	Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. <i>Oncologist</i> , 2020, 25, e909-e919.	3.7	2
15	Trial Design: Overview of Study Designs. <i>Success in Academic Surgery</i> , 2020, , 37-45.	0.1	1
16	CoxPhLb: An R Package for Analyzing Length Biased Data under Cox Model. <i>R Journal</i> , 2020, 12, 118.	1.8	0
17	The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. <i>Journal of Cancer</i> , 2019, 10, 2635-2642.	2.5	3
18	Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women. <i>Value in Health</i> , 2019, 22, 185-193.	0.3	16

#	ARTICLE	IF	CITATIONS
19	Semiparametric Model for Bivariate Survival Data Subject to Biased Sampling. <i>Journal of the Royal Statistical Society Series B: Statistical Methodology</i> , 2019, 81, 409-429.	2.2	4
20	Estimating the frequency of indolent breast cancer in screening trials. <i>Statistical Methods in Medical Research</i> , 2019, 28, 1261-1271.	1.5	6
21	Model diagnostics for the proportional hazards model with length-biased data. <i>Lifetime Data Analysis</i> , 2019, 25, 79-96.	0.9	5
22	Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 615-623.	2.5	12
23	Analysis of Restricted Mean Survival Time for Length-biased Data. <i>Biometrics</i> , 2018, 74, 575-583.	1.4	9
24	Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2630-2638.	1.6	38
25	Reconstruction in the Metastatic Breast Cancer Patient: Results from the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2018, 25, 3125-3133.	1.5	9
26	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1207.	7.1	56
27	Sample size calculations for prevalent cohort designs. <i>Statistical Methods in Medical Research</i> , 2017, 26, 280-291.	1.5	5
28	Nonparametric and semiparametric regression estimation for length-biased survival data. <i>Lifetime Data Analysis</i> , 2017, 23, 3-24.	0.9	15
29	Estimating treatment effects in observational studies with both prevalent and incident cohorts. <i>Canadian Journal of Statistics</i> , 2017, 45, 202-219.	0.9	6
30	Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway. <i>Leukemia</i> , 2017, 31, 1314-1324.	7.2	29
31	Semiparametric density ratio modeling of survival data from a prevalent cohort. <i>Biostatistics</i> , 2017, 18, 62-75.	1.5	5
32	Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1218-1225.	0.8	6
33	A Phase I Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers. <i>Molecular Therapy</i> , 2016, 24, 1484-1491.	8.2	45
34	Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033). <i>Breast Cancer Research</i> , 2016, 18, 93.	5.0	7
35	Prospective Study of Surgical Decision-making Processes for Contralateral Prophylactic Mastectomy in Women With Breast Cancer. <i>Annals of Surgery</i> , 2016, 263, 178-183.	4.2	56
36	Practical Implications of the Publication of Consensus Guidelines by the American Society for Radiation Oncology: Accelerated Partial Breast Irradiation and the National Cancer Data Base. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 338-348.	0.8	21

#	ARTICLE	IF	CITATIONS
37	A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. <i>European Urology</i> , 2016, 69, 855-862.	1.9	228
38	Semiparametric maximum likelihood inference for truncated or biased-sampling data. <i>Statistica Sinica</i> , 2016, , .	0.3	2
39	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 407-416.	2.5	68
40	Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1311.	7.1	65
41	Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database. <i>Journal of Clinical Oncology</i> , 2014, 32, 2018-2024.	1.6	113
42	Surgeon Influence on Use of Needle Biopsy in Patients With Breast Cancer: A National Medicare Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2206-2216.	1.6	24
43	Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. <i>Annals of Oncology</i> , 2014, 25, 384-391.	1.2	102
44	First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 417-425.	2.5	7
45	Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk. <i>British Journal of Cancer</i> , 2014, 111, 1542-1551.	6.4	42
46	Score Estimating Equations from Embedded Likelihood Functions Under Accelerated Failure Time Model. <i>Journal of the American Statistical Association</i> , 2014, 109, 1625-1635.	3.1	11
47	Cost of Contralateral Prophylactic Mastectomy. <i>Annals of Surgical Oncology</i> , 2014, 21, 2823-2830.	1.5	30
48	Semiparametric accelerated failure time model for length-biased data with application to dementia study. <i>Statistica Sinica</i> , 2014, 24, 313-333.	0.3	15
49	Statin use in primary inflammatory breast cancer: a cohort study. <i>British Journal of Cancer</i> , 2013, 109, 318-324.	6.4	80
50	Empirical likelihood-based confidence intervals for length-biased data. <i>Statistics in Medicine</i> , 2013, 32, 2278-2291.	1.6	6
51	An efficient sequential design of clinical trials. <i>Journal of Statistical Planning and Inference</i> , 2013, 143, 283-295.	0.6	4
52	Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center. <i>European Urology</i> , 2013, 64, 307-313.	1.9	147
53	A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer. <i>Cancer</i> , 2013, 119, 540-547.	4.1	74
54	Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy. <i>Cancer Immunology Research</i> , 2013, 1, 229-234.	3.4	178

#	ARTICLE	IF	CITATIONS
55	Likelihood approaches for the invariant density ratio model with biased-sampling data. <i>Biometrika</i> , 2012, 99, 363-378.	2.4	5
56	Nomogram to Predict the Benefit of Radiation for Older Patients With Breast Cancer Treated With Conservative Surgery. <i>Journal of Clinical Oncology</i> , 2012, 30, 2837-2843.	1.6	86
57	A Steroid Receptor- μ MicroRNA Switch Regulates Life Span in Response to Signals from the Gonad. <i>Science</i> , 2012, 338, 1472-1476.	12.6	97
58	Imputation for semiparametric transformation models with biased-sampling data. <i>Lifetime Data Analysis</i> , 2012, 18, 470-503.	0.9	4
59	Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. <i>Cancer</i> , 2012, 118, 5637-5643.	4.1	52
60	p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers. <i>PLoS ONE</i> , 2012, 7, e30206.	2.5	71
61	Prostate Cancer Incidence in U.S. Air Force Aviators Compared with Non-Aviators. <i>Aviation, Space, and Environmental Medicine</i> , 2011, 82, 1067-1070.	0.5	6
62	Buckley-James-Type Estimator with Right-Censored and Length-Biased Data. <i>Biometrics</i> , 2011, 67, 1369-1378.	1.4	30
63	Risk-Specific Optimal Cancer Screening Schedules: An Application to Breast Cancer Early Detection. <i>Statistics in Biosciences</i> , 2011, 3, 169-186.	1.2	6
64	Maximum Likelihood Estimations and EM Algorithms With Length-Biased Data. <i>Journal of the American Statistical Association</i> , 2011, 106, 1434-1449.	3.1	53
65	A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 284-284.	1.6	2
66	Statistical Methods for Analyzing Right-Censored Length-Biased Data under Cox Model. <i>Biometrics</i> , 2010, 66, 382-392.	1.4	103
67	Non-Parametric Tests for Right-Censored Data with Biased Sampling. <i>Journal of the Royal Statistical Society Series B: Statistical Methodology</i> , 2010, 72, 609-630.	2.2	24
68	Hexaminolevulinate Guided Fluorescence Cystoscopy Reduces Recurrence in Patients With Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2010, 184, 1907-1914.	0.4	243
69	Cost-Effectiveness Analysis of Mammography and Clinical Breast Examination Strategies: A Comparison with Current Guidelines. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 718-725.	2.5	40
70	Randomized Phase II Trial Evaluation of Erectile Function after Attempted Unilateral Cavernous Nerve-Sparing Retropubic Radical Prostatectomy With Versus Without Unilateral Sural Nerve Grafting for Clinically Localized Prostate Cancer. <i>European Urology</i> , 2009, 55, 1135-1144.	1.9	62
71	Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004. <i>Cancer</i> , 2009, 115, 2041-2051.	4.1	20
72	Analyzing Length-Biased Data With Semiparametric Transformation and Accelerated Failure Time Models. <i>Journal of the American Statistical Association</i> , 2009, 104, 1192-1202.	3.1	102

#	ARTICLE	IF	CITATIONS
73	Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma. <i>Urology</i> , 2009, 73, 337-341.	1.0	32
74	A Semiparametric Regression Cure Model for Interval-Censored Data. <i>Journal of the American Statistical Association</i> , 2009, 104, 1168-1178.	3.1	58
75	Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray. <i>Molecular Carcinogenesis</i> , 2008, 47, 678-685.	2.7	33
76	Monitoring late-onset toxicities in phase I trials using predicted risks. <i>Biostatistics</i> , 2008, 9, 442-457.	1.5	45
77	Prognostic Role of Detection Method and Its Relationship with Tumor Biomarkers in Breast Cancer: The University of Texas M. D. Anderson Cancer Center Experience. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1096-1103.	2.5	27
78	Tamoxifen Chemoprevention Treatment and Time to First Diagnosis of Estrogen Receptor-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1448-1453.	6.3	16
79	Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System. <i>Leukemia and Lymphoma</i> , 2007, 48, 1150-1160.	1.3	60
80	CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3967-3972.	7.1	445
81	Adaptive design: estimation and inference with censored data in a semiparametric model. <i>Biostatistics</i> , 2007, 8, 306-322.	1.5	5
82	Correlation between CpG methylation profiles and hormone receptor status in breast cancers. <i>Breast Cancer Research</i> , 2007, 9, R57.	5.0	130
83	Inference of Tamoxifen's Effects on Prevention of Breast Cancer From a Randomized Controlled Trial. <i>Journal of the American Statistical Association</i> , 2007, 102, 1235-1244.	3.1	8
84	Marginal Analysis of Correlated Failure Time Data with Informative Cluster Sizes. <i>Biometrics</i> , 2007, 63, 663-672.	1.4	38
85	Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 347-356.	2.5	26
86	Prognostic significance of monocytosis in patients with myeloproliferative disorders. <i>Leukemia and Lymphoma</i> , 2006, 47, 417-423.	1.3	23
87	Optimization of Breast Cancer Screening Modalities. , 2006, , 405-420.		2
88	Chapter 6: Modeling the Impact of Treatment and Screening on U.S. Breast Cancer Mortality: A Bayesian Approach. <i>Journal of the National Cancer Institute Monographs</i> , 2006, 2006, 30-36.	2.1	90
89	Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic Assay. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 299.	7.4	228
90	Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 5442-5447.	7.0	81

#	ARTICLE	IF	CITATIONS
91	Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. <i>Leukemia</i> , 2005, 19, 1567-1572.	7.2	33
92	A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose-Finding Trial. <i>Biometrics</i> , 2005, 61, 343-354.	1.4	86
93	Adaptive Design and Estimation in Randomized Clinical Trials with Correlated Observations. <i>Biometrics</i> , 2005, 61, 362-369.	1.4	10
94	Nonparametric Estimation of Asymptomatic Duration from a Randomized Prospective Cancer Screening Trial. <i>Biometrics</i> , 2005, 61, 992-999.	1.4	8
95	Symptomatic local recurrence of prostate carcinoma after radiation therapy. <i>Cancer</i> , 2005, 103, 2060-2066.	4.1	9
96	Estimation of age-specific sensitivity and sojourn time in breast cancer screening studies. <i>Statistics in Medicine</i> , 2005, 24, 3123-3138.	1.6	15
97	Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. <i>Biostatistics</i> , 2005, 6, 604-614.	1.5	20
98	A Model-Based Comparison of Breast Cancer Screening Strategies: Mammograms and Clinical Breast Examinations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 529-532.	2.5	29
99	Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 810.	7.4	309
100	Self-Designing Trial Combined with Classical Group Sequential Monitoring. <i>Journal of Biopharmaceutical Statistics</i> , 2005, 15, 667-675.	0.8	14
101	Bayesian adaptive designs for clinical trials. <i>Biometrika</i> , 2005, 92, 633-646.	2.4	32
102	Role of Detection Method in Predicting Breast Cancer Survival: Analysis of Randomized Screening Trials. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1195-1203.	6.3	216
103	RESPONSE: Re: Role of Detection Method in Predicting Breast Cancer Survival: Analysis of Randomized Screening Trials. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1854-1854.	6.3	0
104	VALIDATION OF CRITERIA USED TO PREDICT EXTRAPROSTATIC CANCER EXTENSION: A TOOL FOR USE IN SELECTING PATIENTS FOR NERVE SPARING RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2005, 174, 1262-1265.	0.4	24
105	Evaluation of Potassium Values in a Cancer Patient Population. <i>Laboratory Medicine</i> , 2005, 36, 95-97.	1.2	1
106	Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors. <i>Clinical Cancer Research</i> , 2004, 10, 33-42.	7.0	38
107	Estimation of a Parameter and Its Exact Confidence Interval Following Sequential Sample Size Reestimation Trials. <i>Biometrics</i> , 2004, 60, 910-918.	1.4	17
108	Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. <i>Cancer</i> , 2004, 100, 1884-1891.	4.1	66

#	ARTICLE	IF	CITATIONS
109	A renal mass in the setting of a nonrenal malignancy. <i>Cancer</i> , 2004, 101, 2195-2201.	4.1	59
110	C-kit receptor expression in acute leukemias—association with patient and disease characteristics and with outcome. <i>Leukemia Research</i> , 2004, 28, 373-378.	0.8	21
111	Is There a Role for Surgery in the Management of Metastatic Urothelial Cancer? The M. D. Anderson Experience. <i>Journal of Urology</i> , 2004, 171, 145-148.	0.4	141
112	EVIDENCE SUPPORTING PREOPERATIVE CHEMOTHERAPY FOR SMALL CELL CARCINOMA OF THE BLADDER: A RETROSPECTIVE REVIEW OF THE M. D. ANDERSON CANCER EXPERIENCE. <i>Journal of Urology</i> , 2004, 172, 481-484.	0.4	225
113	Correlation of Metastasis Related Gene Expression and Relapse-Free Survival in Patients With Locally Advanced Bladder Cancer Treated With Cystectomy and Chemotherapy. <i>Journal of Urology</i> , 2004, 171, 570-574.	0.4	78
114	Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction. <i>Cancer</i> , 2003, 97, 450-456.	4.1	73
115	The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Cancer</i> , 2003, 98, 1681-1688.	4.1	23
116	Evaluation of loss of heterozygosity before and after interferon therapy in patients with hepatitis C virus infection who developed hepatocellular carcinoma during follow up. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 1364-1372.	2.8	1
117	Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia. <i>Leukemia</i> , 2003, 17, 990-993.	7.2	14
118	Evaluation of Age and Comorbidity as Risk Factors After Laparoscopic Urological Surgery. <i>Journal of Urology</i> , 2003, 170, 1115-1120.	0.4	84
119	Sample Size Reestimation for Clinical Trials With Censored Survival Data. <i>Journal of the American Statistical Association</i> , 2003, 98, 418-426.	3.1	24
120	Multimodality Management of Urachal Carcinoma: The M. D. Anderson Cancer Center Experience. <i>Journal of Urology</i> , 2003, 169, 1295-1298.	0.4	248
121	Intrinsic flexibility and gating mechanism of the potassium channel KcsA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 1949-1953.	7.1	58
122	A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. <i>Gut</i> , 2002, 50, 857-860.	12.1	375
123	Increased Apoptosis in Metastatic Human Colonic Adenocarcinomas. <i>Cancer Biology and Therapy</i> , 2002, 1, 58-63.	3.4	24
124	Myelodysplastic syndrome is not merely "preleukemia". <i>Blood</i> , 2002, 100, 791-798.	1.4	127
125	Conformational pathways in the gating of <i>Escherichia coli</i> mechanosensitive channel. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 5999-6004.	7.1	81
126	Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. <i>Cancer</i> , 2002, 94, 14-17.	4.1	36

#	ARTICLE	IF	CITATIONS
127	Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels. <i>Leukemia Research</i> , 2002, 26, 399-402.	0.8	22
128	Screening Sensitivity and Sojourn Time From Breast Cancer Early Detection Clinical Trials: Mammograms and Physical Examinations. <i>Journal of Clinical Oncology</i> , 2001, 19, 3490-3499.	1.6	121
129	High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. <i>Cancer</i> , 2001, 92, 7-14.	4.1	46
130	High-dose chemotherapy in high-risk myelodysplastic syndrome. <i>Cancer</i> , 2001, 92, 1999-2015.	4.1	88
131	OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma. <i>Cancer</i> , 2001, 92, 2837-2844.	4.1	94
132	Testing the Independence of Two Diagnostic Tests. <i>Biometrics</i> , 2001, 57, 1009-1017.	1.4	23
133	Permutation tests for comparing marginal survival functions with clustered failure time data. <i>Statistics in Medicine</i> , 2000, 19, 2963-2973.	1.6	23
134	Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. <i>Blood</i> , 2000, 95, 72-77.	1.4	97
135	The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis. <i>New England Journal of Medicine</i> , 2000, 342, 1946-1952.	27.0	2,352
136	Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. <i>Blood</i> , 2000, 95, 72-77.	1.4	2
137	Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue: An Uncontrolled Trial. <i>Annals of Internal Medicine</i> , 1999, 131, 88.	3.9	206
138	Parametric estimation procedures for screening programmes: stable and nonstable disease models for multimodality case finding. <i>Biometrika</i> , 1999, 86, 503-515.	2.4	48
139	Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 1999, 9, 44-53.	2.5	10
140	Assessing effects on long-term survival after early termination of randomized trials. , 1999, 5, 55-66.		1
141	Statistical Inference for Self-Designing Clinical Trials with a One-Sided Hypothesis. <i>Biometrics</i> , 1999, 55, 190-197.	1.4	132
142	Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. <i>Gastroenterology</i> , 1999, 117, 350-358.	1.3	129
143	Parametric likelihoods for multiple non-fatal competing risks and death. , 1998, 17, 999-1015.		18
144	Parallel conjugate gradient performance for least-squares finite elements and transport problems. <i>International Journal for Numerical Methods in Fluids</i> , 1998, 28, 1421-1440.	1.6	14

#	ARTICLE	IF	CITATIONS
145	Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers. <i>Clinical Cancer Research</i> , 1998, 4, 1251-61.	7.0	44
146	ESTIMATING ASYMPTOMATIC DURATION IN CANCER: THE AIDS CONNECTION. <i>Statistics in Medicine</i> , 1997, 16, 627-644.	1.6	16
147	Age-specific prostate-specific antigen: A reassessment. <i>Prostate</i> , 1996, 29, 70-77.	2.3	19